Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Generated: May 29, 2017

DrugPatentWatch Database Preview

Eltrombopag olamine - Generic Drug Details

« Back to Dashboard

What are the generic sources for eltrombopag olamine and what is the scope of eltrombopag olamine patent protection?

Eltrombopag olamine
is the generic ingredient in one branded drug marketed by Novartis Pharms Corp and is included in two NDAs. There are twenty-three patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Eltrombopag olamine has one hundred and seventy-one patent family members in forty-one countries.

There are two drug master file entries for eltrombopag olamine. Two suppliers are listed for this compound.

Summary for Generic Name: eltrombopag olamine

Drug Master File Entries: see list2
Suppliers / Packagers: see list2
Bulk Api Vendors: see list48
Clinical Trials: see list41
Patent Applications: see list105
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:eltrombopag olamine at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis Pharms Corp
eltrombopag olamine
TABLET;ORAL022291-004Oct 20, 2011RXYesNo7,332,481*PED► SubscribeY► Subscribe
Novartis Pharms Corp
eltrombopag olamine
TABLET;ORAL022291-005Nov 16, 2012RXYesYes7,547,719*PED► SubscribeY► Subscribe
Novartis Pharms Corp
eltrombopag olamine
TABLET;ORAL022291-001Nov 20, 2008RXYesNo8,062,665*PED► SubscribeY► Subscribe
Novartis Pharms Corp
eltrombopag olamine
TABLET;ORAL022291-002Nov 20, 2008RXYesNo► Subscribe► Subscribe
Novartis Pharms Corp
eltrombopag olamine
FOR SUSPENSION;ORAL207027-001Aug 24, 2015RXYesYes6,280,959► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Subscribe for Complete Access

  • Formulary management
  • Identify first generic entrants
  • Obtain formulation and manufacturing information

► Plans and Pricing

Expired Orange Book Patents

 Available with subscription

Paragraph IV Activity

 Available with subscription

Patent Maintenance

 Available with subscription

Non-Orange Book Patents

 Available with subscription

International Patents

 Available with subscription

Supplementary Protection Certificates

 Available with subscription

« Back to the Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:

Google Plus